William Blair initiated coverage of BridgeBio (BBIO) with an Outperform rating and fair value estimate of $93.03 per share. BridgeBio is a commercial-stage biotech company in a “unique position” with an accelerating launch in Attruby, near-term new drug application submissions setting up late-2026 or early-2027 launches, and regulatory submission for infigratinib in achondroplasia planned for second half 2026, the analyst tells investors in a research note. Blair believes Attruby is well positioned for growth.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BBIO:
- JPMorgan ups BridgeBio target, adds to Analyst Focus List
- BridgeBio Pharma: Advancing Late-Stage Pipeline and Near-Term Catalysts Underpin Reaffirmed Buy and $100 Target
- BridgeBio Pharma Earnings Call Signals Profitable Pivot
- BridgeBio price target raised to $95 from $86 at Truist
- BridgeBio price target raised to $98 from $96 at Morgan Stanley